Biocon defends limited trial patients for Itolizumab nod, says followed science of "highest order"

The company is marketing the drug as a replacement to Roche Pharma ’s Tocilizumab (originally approved for rheumatoid arthritis) that is currently in off label use (it means use of a drug for an unapproved indication) among Covid-19 patients who suffer from cytokine release syndrome (CRS) or “cytokine storm”.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news